Who is Arsanis?

- Clinical stage company developing novel mAbs to prevent and treat severe infectious diseases with the greatest unmet need
- Founded in 2010: Research team in Vienna, Austria, Development/Corporate team in Waltham, MA, USA
- ASN100, a combination mAb product for the prevention of S. aureus pneumonia in high risk, mechanically ventilated patients currently in Ph. 2

Arsanis has a deep pipeline of mAb products for key pathogens

- mAbs to Gram-negative pathogens offer new approach to target specific MDR strains
  - ASN200 for Escherichia coli
  - Combats hypervirulent MDR E. coli ST131-O25b
  - Directly bactericidal, potentiates antibiotics, anti-inflammatory effect without immune cells
  - Currently in pre-clinical development

ASN300 for Klebsiella pneumoniae

- Targets bacterial surface structures and has multiple modes of action
- In vivo proof-of-concept demonstrated

mAbs for Infectious Diseases

- mAbs have the potential to prevent and treat serious infections to improve outcomes and address the threat of antibiotic resistance
- mAbs, unlike traditional antibiotics, selectively target specific pathogens and pathogenic processes; offering new ways of treating and preventing serious infections while minimizing the collateral damage from antibiotic overuse, emerging resistance, and microbiome disruption
- mAbs can result in clinical and health economic benefits to patients and providers, and usher in a new era in infection prevention and management

Contact

Eszer Nagy, MD PhD
Chief Scientific Officer of Arsanis ● Managing Director of Arsanis Biosciences
Helmut-Quattinger-Gasse 2/1 ● 1030 Vienna ● Austria
eszternagy@arsanis.com ● +43 (1) 799 0117

Financing and Partnerships

- $45M secured from top-tier life science VC investors since 2010
- Multiple collaborations with leading infectious disease experts from industry, academic, and clinical research
- Strategic collaboration for antibody discovery for ASN100, ASN400 and ASN500 with Adimab and their industry premier human antibody discovery and optimization platform